RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration
Sarcopenia, Connective Tissue Diseases in Old Age, Musculoskeletal Abnormalities
About this trial
This is an interventional prevention trial for Sarcopenia focused on measuring Sarcopenia, Vibration, Hydroxymethylbutyrate
Eligibility Criteria
Inclusion Criteria:
- Subjects aged 65 years or above
Subjects failed in AWGS algorithm
- skeletal muscle mass by BIA (male at <7.0 kg/m^2, female at <5.7 kg/m^2), and
- handgrip strength (male at <26 kg, female at <18kg), and/or
- gait speed test (<1m/s)
Exclusion Criteria:
- Subjects with pathological bone diseases
- Subjects with chronic inflammatory condition (e.g. rheumatoid arthritis)
- Subjects with neurological problems
- Subjects receiving regular exercise
- Subjecs who are chair-/bed- bound
- Subjects with malignancy
- Subjects with cardiovascular concern such as with pace-maker in-situ
- Subjects with acute fractures or severe osteoarthritis
Sites / Locations
- Evangelical Luthera Church Social Service - Hong Kong
- The Chinese University of Hong Kong Jockey Club Centre for Osteoporosis Care and ControlRecruiting
- The Chinese University of Hong Kong, Department of Orthopaedics and Traumatology, 1/F Li Ka Shing Outpatient Clinic (North), PWHRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Placebo Comparator
Active Comparator
Active Comparator
Experimental
Control Group
HMB only Group
VT only Group
HMB + VT Group
Subjects assigned to Contro Group will not receive VT or HMB. They will receive daily protein supplement for 6 months.
Subjects assigned to HMB only Group will receive HMB supplement at 3g/day and daily protein supplement for 6 months.
Subjects assigned to VT only Group will receive VT (0.3g, 35Hz, at least 3 times/week) and daily protein supplement for 6 months
Subjects assigned to HMB + VT Group will receive HMB supplement at 3g/day, VT at least 3 times/week and daily protein supplement for 6 months.